Table 3. Characteristics of de novo donor-specific antibodies leading to AMR in KTRs according to detection timing.
| De novo DSA | Entire DSA (n = 16) | 6 months DSA (n = 2) | 12 months DSA (n = 4) | ≥ 24 months DSA (n = 7) | Clinically indicated (n = 3) | DSA (+) AMR (−) (n = 13) | DSA (+) AMR (+) (n = 3) | P value | |
|---|---|---|---|---|---|---|---|---|---|
| Mean No. | 1.8 ± 1.2 | 1.0 | 1.0 | 2.4 ± 1.5 | 2.0 ± 1.0 | 1.7 ± 1.3 | 2.3 ± 1.2 | 0.364 | |
| Average MFI | 7,399.3 ± 5,470.4 | 2,016.0 ± 732.6 | 8,531.8 ± 8,119.2 | 7,773.9 ± 4,515.4 | 8,604.0 ± 5,468.8 | 6,692.6 ± 5,823.1 | 10,461.3 ± 1,917.4 | 0.296 | |
| DQ | 7,174.3 ± 6,520.9 | 2,016.0 ± 732.6 | 8,531.8 ± 8,119.2 | 6,451.7 ± 5,269.7 | 12,234.6 ± 8,471.5 | 7,448.1 ± 6,812.6 | 11,600.0 ± 978.6 | 0.060 | |
| DR | 5,169.0 ± 4,992.7 | 0 | 0 | 3,614.5 ± 5,427.0 | 1,904.0 ± 1,717.9 | 4,600.5 ± 4,212.9 | 6,306.0 ± 8,216.6 | 0.738 | |
| Peak MFI | 8,611.4 ± 6,588.0 | 2,016.0 ± 732.6 | 8,531.8 ± 8,119.2 | 8,949.0 ± 5,408.8 | 12,327.0 ± 8,601.1 | 7,737.3 ± 7,039.6 | 12,399.3 ± 1,300.9 | 0.364 | |
| DQ | 8,174.9 ± 6,614.8 | 2,016.0 ± 732.6 | 8,531.8 ± 8,119.2 | 6,783.3 ± 5,649.5 | 12,327.0 ± 8,601.1 | 7,725.5 ± 7,028.7 | 11,095.5 ± 265.2 | 0.111 | |
| DR | 5,810.0 ± 5,961.3 | 0 | 0 | 4,164.0 ± 6,351.8 | 1,904.0 ± 1,717.9 | 5,343.8 ± 5,687.4 | 6,742.5 ± 8,833.9 | 0.819 | |
| Number × Average MFI | 15,155.9 ± 16,166.5 | 2,016.0 ± 732.6 | 8,531.8 ± 8,119.2 | 20,255.0 ± 18,800.9 | 20,850.0 ± 20,013.5 | 13,089.1 ± 16,581.0 | 24,112.0 ± 12,747.6 | 0.189 | |
| DQ | 11,722.0 ± 12,076.2 | 2,016.0 ± 732.6 | 8,531.8 ± 8,119.2 | 11,485.9 ± 11,996.8 | 18,945.3 ± 19,127.3 | 10,761.8 ± 12,463.6 | 17,746.0 ± 9,670.4 | 0.467 | |
| DR | 11,071.2 ± 14,840.7 | 0 | 0 | 8,673.6 ± 14,681.4 | 1,904.0 ± 1,717.9 | 7,313.3 ± 9,612.5 | 18,587.0 ± 25,584.5 | 0.644 | |
| The average time to first detection, mon | 24.0 ± 14.8 | 6.5 ± 0.7 | 12.3 ± 1.9 | 33.1 ± 11.8 | 30.0 ± 17.3 | 24.5 ± 15.1 | 22.0 ± 16.6 | 0.636 | |
| Type of DSA (No.) | DQ (10), DR (1), DQ + DR (5) | DQ (2) | DQ (4) | DQ (3), DR (1), DQ + DR (3) | DQ (1), DQ + DR (2) | DQ (9), DR (0), DQ + DR (4) | DQ (1), DR (1), DQ + DR (1) | ||
| TAC trough levels, ng/mL | |||||||||
| 0–2 mon | 6.63 ± 1.29 | 6.61 ± 1.23 | 0.978 | ||||||
| 3–6 mon | 4.98 ± 1.38 | 6.54 ± 0.98 | 0.090 | ||||||
| 7–12 mon | 4.63 ± 2.18 | 5.66 ± 0.99 | 0.446 | ||||||
| CV (%) | 26.4 ± 17.3 | 17.6 ± 1.1 | 0.093 | ||||||
Values are shown as mean ± standard deviation. P value shows significance of the difference in values between DSA (+) AMR (−) and DSA (+) AMR (+).
KTRs = kidney transplant recipients, DSA = donor-specific anti-human leukocyte antigens antibodies, AMR = antibody-mediated rejection, MFI = mean fluorescence intensity, TAC = tacrolimus, CV = coefficient of variation.